STOCK TITAN

Myomo to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Myomo, Inc. (NYSE American: MYO), a company specializing in wearable medical robotics, is set to present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12 to 14 in New York City. The CEO, Paul Gudonis, and CFO, David Henry, will participate virtually. A webcast of their presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. Eastern time. Myomo develops MyoPro, a powered upper limb orthosis aimed at restoring function for patients with neurological disorders and paralysis, improving daily living activities.

Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference. The Conference is being held September 12 – 14, both virtually and in New York City. Paul Gudonis, chief executive officer, and David Henry, chief financial officer, will participate virtually. A webcast of the presentation will be available on-demand beginning September 12, 2022 at 7:00 a.m. Eastern time here. The link will also be posted in the Investor’s section of Myomo’s website.

Management will be available for virtual one-on-one meetings with the investment community during the conference. Please contact H.C. Wainwright if you would like to schedule a meeting.

About Myomo, Inc.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally. For more information, please visit www.myomo.com.

For Myomo:

ir@myomo.com

LHA Investor Relations

Kim Sutton Golodetz

212-838-3777

kgolodetz@lhai.com

Source: Myomo, Inc.

FAQ

What is the event Myomo is presenting at?

Myomo is presenting at the H.C. Wainwright 24th Annual Global Investment Conference from September 12 to 14, 2022.

Who will represent Myomo at the conference?

CEO Paul Gudonis and CFO David Henry will represent Myomo at the conference.

When can I watch Myomo's presentation?

Myomo's presentation will be available on-demand starting September 12, 2022, at 7:00 a.m. Eastern time.

What is Myomo's stock symbol?

Myomo's stock symbol is MYO, listed on NYSE American.

What does Myomo's MyoPro product do?

MyoPro is a powered upper limb orthosis that helps restore function to individuals with upper limb paralysis due to neurological disorders.

Myomo Inc.

NYSE:MYO

MYO Rankings

MYO Latest News

MYO Stock Data

152.74M
24.90M
13.04%
51.35%
3.38%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
BOSTON